Evaluating Evenamide 15 mg Twice Daily as Add-On Therapy in Adults with Treatment-Resistant Schizophrenia Compared to Placebo A 12-Week Randomized, Double-Blind Study
Led by Newron Pharmaceuticals SPA · Updated on 2026-09-10
400
Participants Needed
19
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Evenamide, a glutamate release modulator, as an add-on treatment for adults with treatment-resistant schizophrenia TRS. The study aims to compare the effects of Evenamide 15 mg twice daily with a placebo, focusing on its efficacy, safety, and tolerability in patients who do not respond adequately to their current stable antipsychotic medications. This is a Phase III, randomized, double-blind, placebo-controlled trial involving approximately 400 participants.
Participants will be randomly assigned to receive either Evenamide capsules 15 mg twice daily or matching placebo capsules twice daily, alongside their standard antipsychotic treatment, for a total of 12 weeks. The treatment period is designed to assess the added benefit of Evenamide compared to placebo when used as an add-on therapy. Both groups will follow the same dosing schedule, and neither participants nor researchers will know which treatment is being administered until the study is complete.
Throughout the 12-week treatment, participants will undergo evaluations including the Positive and Negative Syndrome Scale PANSS, Clinical Global Impression scores, and assessments of personal and social performance and quality of life. Safety will be closely monitored by tracking adverse events during treatment and for 30 days after the treatment period ends. Participants adherence to prescribed antipsychotic treatment will be observed, and the total study duration includes the treatment phase plus a safety follow-up period.
CONDITIONS
Brief Title
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
Research Team
N
Newron Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Evenamide 15 mg bid plus ongoing antipsychotic
Placebo plus ongoing antipsychotic
What is it?
Evenamide is a glutamate release modulator administered as 15 mg capsules twice daily for 12 weeks as an add-on to ongoing antipsychotic medication.
Placebo capsules are given twice daily for 12 weeks as an add-on to ongoing antipsychotic treatment, with identical appearance to Evenamide.
Role in trial
Evaluates Evenamide as an investigational add-on therapy for adults with treatment-resistant schizophrenia.
Serves as the control arm for assessing the effects of investigational Evenamide add-on therapy.
Primary use
Investigational add-on treatment intended to improve symptoms in adults with treatment-resistant schizophrenia beyond current antipsychotic therapy.
Add-on placebo used to measure changes attributable to Evenamide, allowing for blinded comparison in treatment-resistant schizophrenia.
How it is given or performed
Evenamide capsules are taken orally, twice daily, for 12 weeks alongside ongoing antipsychotic medication.
Placebo capsules are taken orally, twice daily, for 12 weeks alongside ongoing antipsychotic medication.
Evidence status
Earlier studies indicate that Evenamide added to antipsychotics may be associated with significant improvement in symptoms of treatment-resistant schizophrenia, including positive and negative symptoms, over periods up to one year; larger phase 3 trials are ongoing to confirm efficacy and safety.
Placebo add-on, when combined with ongoing antipsychotic therapy, does not provide active therapeutic benefit for schizophrenia symptoms beyond the effect of continued antipsychotic medication.
Important limitations
Evidence is still accruing, and larger, longer-term studies are needed to establish effectiveness and safety. Evenamide acts as an add-on to ongoing antipsychotic therapy, so current antipsychotic effects and potential adverse interactions must be considered. Results may not generalize beyond the trial population with documented treatment resistance.
Placebo contains no active medication, so improvements observed are attributable to ongoing antipsychotic therapy and the effect of study participation. Placebo-controlled findings may not reflect comparative effectiveness with other established add-on treatments.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Age 18 years or older
Female participants must have negative pregnancy tests at screening and baseline, not be lactating, and agree to use contraception unless not of childbearing potential
Diagnosis of schizophrenia according to DSM-5-TR criteria
Treatment-resistant to antipsychotics as defined by TRRIP working group
Currently receiving stable standard antipsychotic therapy at minimal recommended doses
Clinical Global Impression - Severity rating from mildly ill to extremely ill at baseline
Brief Psychiatric Rating Scale (BPRS) total score of 45 or higher at screening and baseline
Positive and Negative Syndrome Scale (PANSS) total score of 70 or higher at baseline
Global Assessment of Functioning (GAF) scale total score 50 or lower
Adherence to prescribed antipsychotic treatment
Provided written informed consent prior to participation
You will not qualify if you...
Diagnosis of schizophreniform disorder, schizoaffective disorder, bipolar disorder, or major depressive disorder
Substance Use Disorder within three months prior to study entry
Current psychosis episode requiring hospitalization for stabilization, unless antipsychotic dose has been stable for 6 weeks prior to screening
Other psychiatric or behavioral disorders
Known suicidal risk or suicide attempt within past 2 years
History of neuroleptic malignant syndrome or priapism
Medical conditions that could affect safety or study evaluations
History or current diagnosis of epilepsy or seizure disorder, seizure within past year, or repeated drug-induced seizures
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 12 weeks
Participants receive either Evenamide 15 mg twice daily or matching placebo capsules as add-on treatment alongside their current antipsychotic medication for 12 weeks.
Regular visits during the 12 weeks
Safety Follow-up
Duration - 30 days
Participants are monitored for adverse events during a 30-day safety follow-up period after treatment ends.
Follow-up visits as needed
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Cognitive Behavioral Therapy to Improve Sleep and Symptoms in Adults with Treatment-Resistant Schizophrenia
Evaluation of Irelands National Forensic Mental Health Service Redevelopment
D-FOREST Study on Patient Recovery, Violence Reduction, and Health Outcomes
Observational Study of Adult Patients from 2019 to 2027
Evaluating Evenamide 15 mg Twice Daily as Add-On Therapy in Adults with Treatment-Resistant Schizophrenia Compared to Placebo A 12-Week Randomized, Double-Blind Study
Neurofeedback Treatment Using Real-time fMRI to Reduce Auditory Hallucinations in Adults With Schizophrenia
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy and safety of evenamide, a glutamate modulator, added to a second-generation antipsychotic in inadequately/poorly responding patients with chronic schizophrenia: Results from a randomized, double-blind, placebo-controlled, phase 3, international clinical trial.
Ravi Anand, Alessio Turolla, Giovanni Chinellato...
Therapeutic Effect of Evenamide, a Glutamate Inhibitor, in Patients With Treatment-Resistant Schizophrenia (TRS): Final, 1-Year Results From a Phase 2, Open-Label, Rater-Blinded, Randomized, International Clinical Trial.
Ravi Anand, Alessio Turolla, Giovanni Chinellato...
Phase 2 Results Indicate Evenamide, A Selective Modulator of Glutamate Release, Is Associated With Clinically Important Long-Term Efficacy When Added to an Antipsychotic in Patients With Treatment-Resistant Schizophrenia.
Ravi Anand, Alessio Turolla, Giovanni Chinellato...